Engineering saRNA Delivery Systems for Therapeutics

RNA medicines have rapidly transformed the landscape of disease prevention and treatment, with mRNA vaccines demonstrating the remarkable potential of RNA-based technologies. However, important challenges remain in improving the potency, durability, safety, and accessibility of RNA therapeutics. Developing delivery systems capable of achieving robust therapeutic effects at lower doses will be critical to unlocking the next generation of RNA medicines.

We are pleased to invite Anna Blakney, PhD, Assistant Professor at the Michael Smith Laboratories and School of Biomedical Engineering at the University of British Columbia, to share her research on engineering self-amplifying RNA (saRNA) technologies and advanced delivery systems for therapeutic applications.

In this webinar, Dr Blakney will discuss the development of next-generation saRNA platforms designed to generate prolonged therapeutic effects while requiring substantially lower doses than conventional RNA approaches. She will explore how engineering RNA constructs and optimising nanoparticle delivery systems can enhance RNA expression, improve therapeutic performance, and enable new applications across infectious diseases, cancer, and genetic disorders.

Key points to be discussed during the session:

• How self-amplifying RNA (saRNA) technologies can achieve potent and durable therapeutic effects at significantly lower doses
• How molecular engineering strategies can be used to optimise saRNA design and performance
• How nanoparticle delivery systems can be engineered to improve the efficiency, safety, and effectiveness of saRNA therapeutics
• The potential of next-generation saRNA platforms for vaccines and therapies targeting infectious diseases, cancer, and genetic disorders